Table 1.
Comparison of clinical data for patients with anti-Mi-2 antibody in a previous report and in the present study.
| Multicenter study* | This study | |
|---|---|---|
| Anti-Mi-2 (+) pts., number (%) | 9/376 (2.4) | 7/124 (5.6) |
| Age at onset, median (range), y | 45 (16–66) | 62 (40–73) |
| Sex, M/F, number | 6/3 | 1/6 |
| Diagnosis, % | ||
| Classical DM | 100 | 100 |
| Clinically amyopathic DM | 0 | 0 |
| Clinical features, % | ||
| Muscle weakness | 100 | 100 |
| Arthritis | 11 | 14 |
| ILD | 11 | 0 |
| Malignancy | 0 | 0 |
| Skin eruptions, % | ||
| Heliotrope rash | 67 | 57 |
| Facial erythema** | 56 | 100 |
| Gottron sign | 89 | 100 |
| Prognosis (alive), % | 100 | 100 |
*Data from [10]. This cohort includes 7 patients used in this study, all of whom were negative for anti-Mi-2 antibodies. **Facial erythema other than heliotrope rash.